Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

North Bud Farms $NBUD.ca Provides Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:49 PM on Tuesday, June 2nd, 2020
  • Signed a definitive agreement to sell all the shares of its U.S. subsidiary, Bonfire Brands USA, Inc.
  • Under the terms of the transaction, the acquiring party is responsible for and guarantees all of BBUSA’s past and future liabilities and capital requirements, including all of the outstanding intercompany debts owed to NORTHBUD up to a maximum of CDN$2 million
  • The acquiror will retain rights to the name “Bonfire Brands” and the Company will no longer proceed with the change of name and symbol that was approved at the last shareholder meeting

TORONTO, June 02, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) provides shareholders with the following corporate update:

U.S. Operations

The Company is pleased to announce that it has signed a definitive agreement to sell all the shares of its U.S. subsidiary, Bonfire Brands USA, Inc. (“BBUSA”), to an entity controlled by Mr. Justin Braune, the President of BBUSA.  The transaction constitutes a related-party transaction as defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the shares of BBUSA sold to the acquiror does not exceed 25% of the Company’s market capitalization.  This determination is based upon the fact that the value of the net assets of BBUSA is negligible as the assets acquired were, and continue to be, highly leveraged.  In light of the current market conditions, it is no longer economically viable for the Company to continue to try to sustain and develop these assets.

Under the terms of the transaction, the acquiring party is responsible for and guarantees all of BBUSA’s past and future liabilities and capital requirements, including all of the outstanding intercompany debts owed to NORTHBUD up to a maximum of CDN$2 million.  The acquiror will retain rights to the name “Bonfire Brands” and the Company will no longer proceed with the change of name and symbol that was approved at the last shareholder meeting. 

“We are pleased with the successful completion of this deal to divest our U.S. holdings as it will significantly improve the Company’s balance sheet and available cash flow, a key Company objective in light of the difficult economic climate brought on by Covid-19,” said Ryan Brown, NORTHBUD’s Executive Chairman and Interim CEO.  “The structure of this transaction represents the achievement of the Company’s previously-announced plan to remove its direct exposure to the U.S. cannabis sector in order to eliminate the increasing administrative and capital costs associated with such holdings.”

Failure-to-File Cease Trade Order Issued
The following is an update on the previously announced management cease trade order (the “MCTO“) issued by the Ontario Securities Commission on March 31, 2020.  The MCTO was issued in connection with the delay by the Company in filing its annual financial statements, management’s discussion and analysis and related officer certifications for the financial year ended November 30, 2019 (collectively, the “Required Filings“) before the prescribed deadline of March 30, 2020.  

Sequence of Events
As previously disclosed, the Company completed two material U.S.-based acquisitions in November 2019, weeks prior to its year-end, thus obliging the Company to include purchase price accounting and post-acquisition activity for both acquired companies into its consolidated financial statements for the financial year ended November 30, 2019.

The Company took decisive steps to augment its capabilities to manage and report on its expanded operations including the appointment of advisors, valuation and taxation experts to assist with the year-end reporting and audit requirements; the appointments of Sean Homuth as CEO in December 2019, Adam Shapero as General Counsel in January 2020, and Jeffrey Stoss as CFO in February 2020; and, the addition of Jennifer Ross-Carriere and Lisa Mayhew as Directors in December 2019 and February 2020 respectively. Unfortunately, Sean Homuth had to take a medical leave of absence from the Company on April 28, 2020, which resulted in some delays to the progress of the year-end audit as he was interim CFO for the Company around the time of the U.S. acquisitions.

Due primarily to the inability of management, and its advisors and auditors to travel to the U.S. to conduct onsite field work, and due to ongoing travel and work restrictions in both Canada and the U.S. imposed by the impact of COVID-19 and the additional audit and reporting work related to the Company’s stated intention to divest of its U.S. operations as announced May 6, 2020, the Company could not complete and file the Required Filings for the year-ended November 30, 2019 and the quarter-ended February 29, 2020 before the end of the May 31, 2020 deadline contemplated by the MCTO.  The Company, its advisors and its independent auditor, are continuing to work diligently to complete the necessary work and the Company intends to make the Required Filings as soon as possible.

In connection with this delay, on June 2, 2020 the Ontario Securities Commission (“OSC“) issued a failure-to-file cease trade order (“FFCTO“) against the Company.

The FFCTO will affect trading in all securities of the Company in Canada and will remain in effect until such time as the Company has made the Required Filings.  This has resulted in a halt in trading of the Company’s shares on the Canadian Securities Exchange (CSE).  Once the Required Filings are made within 90 days of the date of the FFCTO, such filings will constitute the Company’s application to have the FFCTO revoked.  The Company will issue a further news release when the Required Filings have been made, and it is expected that the Company’s stock will resume trading on the Canadian Securities Exchange at that time.

The FFCTO, among other things, (i) revokes the MCTO in respect of certain officers of the Company, which prohibited those officers from trading in the Company’s securities until after the Company cured its disclosure defaults; and (ii) prohibits any person or company from trading, directly or indirectly, in any security of the Company in the Province of Ontario, and in every other province or territory of Canada in which the Company is a reporting issuer and in which Multilateral Instrument 11-103 – Failure-to-File Cease Trade Orders in Multiple Jurisdictions applies.

A copy of the FFCTO will be posted on the website of the Canadian Securities Administrators at cto-iov.csa-acvm.ca.  The Company will also post a copy of the FFCTO on the Company’s website.

Private Placement Offering Suspended
The Company also wishes to announce that it has voluntarily suspended the anticipated closing of the previously announced private placement offering of up to $2,000,000 of $0.05 Units until the FFCTO is revoked. The Company did not accept any of the subscriptions and did not issue any securities under the private placement.   At this time, the Company continues to evaluate options to preserve shareholder value and provide the Company with the required financial and operational resources required for ongoing operations. During the FFCTO period the Company will continue to update shareholders on the progression of these initiatives.

Additional Management Update to Follow Shortly
Management will be delivering a comprehensive business update to the Company’s shareholders in the coming days, where it will provide further details regarding the Company’s current position and outline plans for moving forward.

About North Bud Farms Inc.
NORTHBUD owns and operates, through its Canadian subsidiary, GrowPros MMP Inc., a licensed cannabis facility in Quebec, Canada. The Company built and owns a state-of-the-art purpose-built cannabis production facility located on 135 acres of agricultural land in Low, Quebec, Canada. The Low, Quebec facility currently has 24,500 sq. ft. of licensed indoor cultivation space; the Company has recently submitted its licence amendment application to Health Canada to add an additional 1,000,000 sq. ft. of outdoor cultivation space.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, the timing of the Company filing the Required Filings. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected] 

Tags: , , ,
Posted in North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Provides Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Primo Nutraceuticals Inc. $PRMO.ca Receives Approval to Sell its Hand Sanitizer on #Amazon.com $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 9:20 AM on Tuesday, June 2nd, 2020
  • Announced that it has received approval from Amazon to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category
  • Through continued perseverance and multiple discussions with customer care, and due to Primo meeting all the required criteria as a licensed establishment with a product that has been licensed and approved by Health Canada, Primo was finally granted permission from Amazon to sell its hand sanitizer on their website.

VANCOUVER, British Columbia, June 02, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that it has received approval from Amazon to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category.

In response to the increasing demand for hand sanitizers in Canada, approximately two months ago Primo filled out an online application to sell its hand sanitizer on Amazon. Primo was granted a Seller Central account but was initially denied the ability to list its hand sanitizer, as Amazon was no longer approving new listings in this category. In early March, Amazon began restricting the types of sellers on its third-party Marketplace platform that are able to sell health and sanitation products, such as: face masks, hand sanitizer, disinfecting wipes/ sprays, isopropyl alcohol, among other products. 

Through continued perseverance and multiple discussions with customer care, and due to Primo meeting all the required criteria as a licensed establishment with a product that has been licensed and approved by Health Canada, Primo was finally granted permission from Amazon to sell its hand sanitizer on their website.

The approval by Amazon could not have come at a better time for the company as its first shipment of hand sanitizer was picked up at their manufacturer on Friday, May 29th, 2020 with an expected delivery of later this week.

In reference to the company’s press release dated March 24th, Primo will be handing out the hand sanitizer as well as promotional samples for procurement departments in the healthcare industry across Canada to essential workers.

The company will also be taking the opportunity to hand out samples to potential customers that are interested in purchasing the hand sanitizer in bulk orders.

To view the product brochure, please visit: https://www.primoceuticals.com/shop#!/Primo-Lemon-Hand-Sanitizer-60/p/197662415/category=0

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC. 

“Andy Jagpal” 

President and Director 

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected] 

To learn more about what this news means to the shareholders visit: 

Shop: www.primoceuticals.com 

www.twitter.com/prmonutra 

https://t.me/PrimoNutraceuticals

www.thrivecbd.org 

www.beautykitchen.net 

www.drinkdefy.com 

Corporate: www.primonutraceuticals.com 

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Tags: , , , , ,
Posted in Featured, PRIMO Nutraceuticals Inc. | Comments Off on Primo Nutraceuticals Inc. $PRMO.ca Receives Approval to Sell its Hand Sanitizer on #Amazon.com $CROP.ca $VP.ca NF.ca $MCOA

Mota Ventures $MOTA.ca Closes $20,000,000 Acquisition of European Pharmaceutical Manufacturer of Natural Psilocybin Extracts $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:41 AM on Tuesday, June 2nd, 2020
  • The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion

VANCOUVER, BC / June 2, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) a leading ecommerce provider of CBD products to consumers in the United States and Europe, is pleased to announce the completion of its’ Cdn$20,000,000 acquisition (the “Transaction“) of all of the outstanding share capital of Verrian Ontario Ltd. (“Verrian“) effective June 1, 2020. Verrian is an established and well advanced European psychedelic medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

Ryan Hoggan, CEO of the Company stated, “The massive shift towards psychedelic derived medicines is no longer in doubt and this acquisition sends a strong signal to the market that Mota Ventures intends to be a serious participant this coming decade. Unlike some companies that use psychedelics as a marketing term, this acquisition of Verrian brings Mota market ready products, world renowned addiction medicine experts, R&D facilities and a 110,000 square foot facility to make it happen. In my opinion this is the most complete psychedelic asset on the market, and therefore should immediately make Mota a market leader in the space.”

Hoggan further added, “In 2020, we have proven our e-commerce ability to acquire tens of thousands of customers and generate millions of dollars in monthly revenues from CBD sales. We intend to bring that same market expertise to bear with our psychedelics business in 2020 and far beyond.”

ACQUISTION PROVIDES MOTA WITH IMMEDIATE ENTRY INTO FAST GROWING $100 BILLION PSYCHEDELICS INDUSTRY

The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion*. Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using psychedelics, including psilocybin.

As a result, psychedelic research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent legalization of Cannabis in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the psychedelics industry.

Verrian has already developed two psilocybin products that are natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs. This is only the beginning with further products in various stages of development.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Verrian operates three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

In consideration for the acquisition of all of the outstanding share capital of Verrian, the Company has issued 54,347,826 common shares (the “Consideration Shares“) to the existing shareholders of Verrian at a deemed price of $0.368 per Consideration Share. 50,543,478 of the Consideration Shares are subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company has arranged for repayment of $150,000 of existing shareholder loans of Verrian, and will arrange for repayment of the balance of $950,000 within sixty days of closing.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Transaction, the Company has paid a finders’ fee of 5,434,783 common shares to certain arms’-length parties who have assisted in facilitating the Transaction. The Company has also paid an administrative fee of 1,086,957 common shares of the Company to a consultant who assisted with the Transaction.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through its powerful eCommerce business, Mota is a leading is a direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the United States through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom.

Through its German-based Verrian operation, Mota is researching and testing the efficacy and application of natural psilocybin products for the treatment of opioid and other life altering addictions. Mota is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD and other natural health products.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: , , , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Closes $20,000,000 Acquisition of European Pharmaceutical Manufacturer of Natural Psilocybin Extracts $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Empower $CBDT.ca #Covid19 Testing Expands to Phase Three and May 2020 Patient Visits Exceed Expectations $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:12 AM on Tuesday, June 2nd, 2020
  • Empower has commenced phase three of COVID-19 testing with a successful pilot of business employee testing
  • Outperforms expected May 2020 patient volume with over 2,300 physician-patient consultations

VANCOUVER BC / June 2nd, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that Empower has successfully conducted COVID-19 antibody business employee testing, solidifying the importance of phase three of the testing program. In addition, the Company conducted 2,302 physician-patient consultations setting a new milestone in patient volume for the month of May.

“We established a four-phase approach to the roll-out of COVID-19 testing, ensuring operational excellence throughout the launch”, said Steven McAuley, Chairman & CEO of Empower. “A positive patient experience is imperative to our success, and therefore, establishing precise disciplined pilot programs that are measured, with quantifiable metrics, insure we can scale effectively.”

In an effort to bolster the the Sun Valley Health division, we have hired three new call centre specialists, two new clinic technicians and a full-time phlebotomist… a trained specialist in drawing blood samples for testing.

“During this time of crisis, our team continues to demonstrate patient advocacy and grows stronger in the face of challenges.” said Dustin Klein, SVP Business Development “We continue to see a record number of patients each week, and with the new diversified health and wellness services being offered, we are fortunate to be able to hire new staff.”

Phase One Testing in clinics in Arizona, utilizing a patient blood draw by clinic phlebotomists, then samples are sent to our laboratory test partner for analysis, with test results expected within 48 hours. This program is active and appointment rates are expanding rapidly.

Phase Two Offering a Rapid COVID-19 antibody test with results in 1-15 minutes. The service will be offered in-clinics using a drive-up service, conducted by Company clinic staff. In addition, an outbound door-step service, to support a variety of consumer, patient and community needs will be offered using certified mobile technicians. The online portal is open to book appointments.

Phase Three Business Employee Testing (BET) programs, offering Rapid COVID-19 testing to businesses on a one-time basis, repeat basis and/or subscription basis, to assist businesses to get back to work safely, has been offered. The phase three pilot programs have successfully been delivered establishing a new revenue stream for the Company.

Phase Four U.S. nationwide roll-out, offering all phases of Company services, that can be accessed online at Company websites and call centers, to purchase Rapid COVID-19 test kits. The Company anticipates phase four services to may commence in Q3 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower $CBDT.ca #Covid19 Testing Expands to Phase Three and May 2020 Patient Visits Exceed Expectations $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

AGORACOM Welcomes TransCanna $TCAN.ca Developing The largest Multi-Purpose #Cannabis Facility in California, $2M In April Revenues and $24.6M Run Rate From Test Facility $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 2:23 PM on Friday, May 29th, 2020
TransCanna (@TransCanna) | Twitter

(CSE: TCAN) (FSE: TH8)

Why TransCanna?

  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

THE FACILITY – 196,000 Sq Ft DALY BUILDING

  • Located in Modesto, California; A key asset for TransCanna
  • 196,000 square foot building has an appraised value, prior to licensing and build out, of US $15m.
  • The indicative value once operational, post-licensing and build out is projected at US $80m.
  • Will be the largest multi-purpose cannabis facility in California.
  • Electricity Rates amongst the lowest in California

Daly building will serve as TransCanna’s operations headquarters and will house manufacturing, distribution and cultivation space.

A breakdown of the 196,000 square feet upon completion will be:

  • 45,000 square feet of manufacturing
  • 50,000 square feet of distribution, packaging and cannabis storage
  • 60,000 square feet of indoor cultivation space
  • 5,000 square feet of independent lab for product testing
  • 36,000 square feet of offices, equipment maintenance, employee areas
https://youtu.be/CbZz_yZQ4nE

Tags: , , , , ,
Posted in AGORACOM Clients (New), All Recent Posts, Featured, TransCanna Holdings Inc. | Comments Off on AGORACOM Welcomes TransCanna $TCAN.ca Developing The largest Multi-Purpose #Cannabis Facility in California, $2M In April Revenues and $24.6M Run Rate From Test Facility $CGC $ACB $APH $CRON.ca $OGI.ca

Hollister $HOLL.ca Launches Tommy Chong’s Cannabis 1:1 Full-Spectrum Elixir $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 11:06 AM on Wednesday, May 27th, 2020
  • Announced the tincture it is manufacturing and distributing for its partner, Tommy Chong’s Cannabis, is officially ready to hit the market
  • The tincture, branded Tommy Chong’s Cannabis™ 1:1 Full Spectrum Elixir, features a sweet berry flavor and 1:1 ratio of CBD to THC; for a total of 1000mg cannabinoids (500mg CBD and 500mg THC).
  • Tommy Chong’s Cannabis™ Full Spectrum Elixir 1:1, is being distributed exclusively by Hollister Cannabis Co.’s distribution partner, Indus Holdings, Inc. (CSE: INDS)

VANCOUVER, May 27, 2020 - Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce the tincture it is manufacturing and distributing for its partner, Tommy Chong’s Cannabis, is officially ready to hit the market.

The tincture, branded Tommy Chong’s Cannabis™ 1:1 Full Spectrum Elixir, features a sweet berry flavor and 1:1 ratio of CBD to THC; for a total of 1000mg cannabinoids (500mg CBD and 500mg THC). True to the manufacturing mission of Hollister Cannabis Co., this 1:1 tincture was crafted in small, artisanal batches for optimal quality and made from premium California-grown cannabis. 

The tincture, Tommy Chong’s Cannabis™ Full Spectrum Elixir 1:1, is being distributed exclusively by Hollister Cannabis Co.’s distribution partner, Indus Holdings, Inc. (CSE: INDS)

CEO of Hollister Biosciences, Carl Saling, shared: “We are thrilled to have Tommy Chong’s Full Spectrum Elixir at Indus’ distribution center, ready to distribute to dispensaries in California. I am super proud of our team – especially through this global pandemic. We have continued to push forward and release a legendary product for a true legend!”

About Tommy Chong’s Cannabis: 

As one-half of the legendary comedy duo Cheech & Chong, Tommy Chong helped pioneer a completely unique brand of comedy directed at the counterculture movement of the early ’70s. At the heart of this brand of entertainment was cannabis. On-screen and off Tommy became a vocal advocate for his favorite herb. In a time where cannabis had to be talked about in whispers, Tommy was a loud voice for the advocacy movement, working tirelessly to destigmatize the use of this healing plant. With the legalization of recreational cannabis, Tommy’s voice continues to ring out loudly, touting its benefits and place in society. Now, Tommy is thrilled to share that passion and knowledge of cannabis with the rest of the world. Using his lifelong connections in the industry, he has made it his personal mission to share the very best product available with his fans and fellow herb connoisseurs. If anyone knows weed, it’s Tommy. And now fans of comedy and cannabis alike can experience the strains and products that Tommy himself has hand-selected.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Tags: , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister $HOLL.ca Launches Tommy Chong’s Cannabis 1:1 Full-Spectrum Elixir $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Empower $CBDT.ca Expands Its Online Education with the Support of EuroLife $EURO.ca to Promote the Benefits of Functional Mushrooms and Psilocybin to Positively Impact Health and Wellness $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:00 AM on Wednesday, May 27th, 2020

– Company is forming a global mushroom education initiative with EuroLife Brands that will leverage the cannvas.me platform

– new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness.

VANCOUVER, BC / May 27th, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with EuroLife Brands (“EuroLife”) that will leverage the cannvas.me platform.

The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of misinformation.

“Our global mushroom education initiative will provide significantly more information pertaining to the treatment of a number of ailments using plant-based treatment options,” said Steven McAuley, chairman and chief executive officer of Empower. “We are proud to bring premium health and wellness products to our patients online and in our clinics and mushrooms are already a part of our expanding product line in this category. We look forward to working with the team at EuroLife to launch this initiative in the very near future.”

“We have an opportunity to be one of the first online education platforms to deliver information on the benefits of using mushrooms for nutrition and health and wellness,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “Our Cannvas.me education portal is scalable and provides quick and easy access to Empower employees, medical professionals and retail consumers who are in need of this important information. We will continue to leverage our technology to move EuroLife forward.”

A report produced by Research and Markets estimates the global mushroom market was over US$38 billion in 2017 and forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. Increasing consumer awareness regarding the health benefits offered by mushrooms is a key factor influencing the growth of the mushroom market at present. Consumer mushroom consumption in supermarkets, restaurants, hotels, and cafeterias are also expected to add to the market demand. Mushrooms are considered a super food as they contain protein, vitamins, minerals and antioxidants, with a great deal of nutritional value and micronutrients. They are low in carbohydrates, high in fiber, and a good source of B-vitamins (riboflavin, pantothenic acid, and niacin), iron, and selenium.

EuroLife and Empower will create a mushroom portal which will leverage the same technology platform used for EuroLife’s cannabis portal and will include educational modules on a wide range of topics. The platform will also incorporate dynamic and interactive elements to facilitate learning.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About EuroLife Brands Inc.

EuroLife Brands is a vertically integrated enterprise focused on the pan-European health and wellness sector.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.I

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower $CBDT.ca Expands Its Online Education with the Support of EuroLife $EURO.ca to Promote the Benefits of Functional Mushrooms and Psilocybin to Positively Impact Health and Wellness $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Spyder Cannabis $SPDR.ca Announces Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:17 AM on Tuesday, May 26th, 2020
  • Company is now awaiting receipt of its RSA (“Retail Store Authorization”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane
  • Company is awaiting a final inspection of its dispensary scheduled for the beginning of June, at which point, it intends to begin operations at its Calgary dispensary, located at 104-58th Ave, SE, suite 140
  • In order to address the challenges presented by the COVID 19 crisis, the company has focus on building up the online and e-commerce components for its US Hemp CBD only locations, in Atlantic City and West Palm Beach.

Vaughan, Ontario–(May 26, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company”) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to provide the following update:

Niagara Falls Cannabis Dispensary

Further to the announcement of receipt of its ROL (“Retail Operator License”), the company is now awaiting receipt of its RSA (“Retail Store Authorization”) for its Niagara Falls dispensary located at 6474 Lundy’s Lane. The company plans to begin operations at the location as soon as the RSA is issued and final inspection is completed, while ensuring it complies with COVID-19 provincial regulations and focusing on its curbside pickup and delivery business.

Calgary Cannabis Dispensary

Further to the announcement of receipt of its Conditional Cannabis License, the company is awaiting a final inspection of its dispensary scheduled for the beginning of June, at which point, it intends to begin operations at its Calgary dispensary, located at 104-58th Ave, SE, suite 140.

Online and e-Commerce

In order to address the challenges presented by the COVID 19 crisis, the company has focus on building up the online and e-commerce components for its US Hemp CBD only locations, in Atlantic City and West Palm Beach. Specifically, the company has launched a US website as well as an affiliate program to generate increased awareness of the Spyder brand at ShopSPDR.com.

Filing Extension of Annual Disclosure Documents Due to COVID-19

Due to circumstances created by the COVID – 19 pandemic Spyder will not be filing its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020 by the scheduled due date of June 1, 2020, as required under section 4.4(b) and section 5.1(1) of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”).

As required by Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements (OSC Instrument 51-502), BC Instrument 51-515 Temporary Exemption from Certain Corporate Finance Requirements (BC Instrument 51-515), Blanket Order 51-517 Temporary Exemption from Certain Corporate Finance Requirements (ASC Blanket Order 51-517) and Manitoba Blanket Order 52-502 Temporary Exemption from Certain Corporate Finance Requirements (Manitoba Blanket Order 52-502), the Company discloses the following:

• The Company’s management and other insiders will be subject to a trading black-out that reflects the principles in Section 9 of National Policy 11-207 – Failure-to-File Cease Trade Orders until its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020;

• The Company expects to file its audited financial statements and related management discussion and analysis for the fiscal year ended January 31, 2020 on or about July 15, 2020

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

For more information, please contact:

Spyder Cannabis Inc.

Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]

Tags: , , , ,
Posted in Spyder Cannabis Inc. | Comments Off on Spyder Cannabis $SPDR.ca Announces Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Eurolife Brands $EURO.ca and Empower Clinics $CBDT.ca Form Global Mushroom Education Initiative $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:59 AM on Tuesday, May 26th, 2020
  • New initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness
  • Will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of mis-information

Toronto, Ontario–(May 26, 2020) –  EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTC PINK: EURPF) (“EuroLife” or the “Company”), a vertically integrated enterprise focused on the pan-European health and wellness sector, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with Empower Clinics Inc. (CSE: CBDT) (OTCQB: EPWCF) (FSE: 8EC) (“Empower“), a vertically integrated and growth-oriented life sciences company.

The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of mis-information.

“Our global mushroom education initiative will provide significantly more information pertaining to the treatment of a number of ailments using these alternative plant-based treatment options,” said Steven McAuley, chairman and chief executive officer of Empower. “We are proud to bring premium health and wellness products to our patients online and in our clinics and mushrooms are already a part of our expanding product line in this category. We look forward to working with the team at EuroLife to launch this initiative in the very near future.”

“We have an opportunity to be one of the first online education platforms to deliver information on the benefits of using mushrooms for nutrition and health and wellness,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “Our Cannvas.me education portal is scalable and provides quick and easy access to Empower employees, medical professionals and retail consumers who are in need of this important information. We will continue to leverage our technology to move EuroLife forward.”

A report produced by Research and Markets estimates the global mushroom market was over US$38 billion in 2017 and forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. Increasing consumer awareness regarding the health benefits offered by mushrooms is a key factor influencing the growth of the mushroom market at present. Consumer mushroom consumption in supermarkets, restaurants, hotels, and cafeterias are also expected to add to the market demand. Mushrooms are considered a super food as they contain protein, vitamins, minerals and antioxidants, with a great deal of nutritional value and micronutrients. They are low in carbohydrates, high in fiber, and a good source of B-vitamins (riboflavin, pantothenic acid, and niacin), iron, and selenium. 

EuroLife and Empower will create a mushroom portal which will leverage the same technology platform used for EuroLife’s cannabis portal and will include educational modules on a wide range of topics. The platform will also incorporate dynamic and interactive elements to facilitate learning.

About Empower Clinics Inc.

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

About EuroLife Brands Inc.

EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTCPK: EURPF) is a vertically integrated enterprise focused on the pan-European health and wellness sector.

For additional information:

Contact: [email protected] or visit EuroLifeBrands.com

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer‘s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company‘s Management‘s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Tags: , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Eurolife Brands $EURO.ca and Empower Clinics $CBDT.ca Form Global Mushroom Education Initiative $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Mota Ventures $MOTA.ca Signs LOI to Acquire Ecommerce Platform Leader Unified Funding, LLC, Which Generated $96.5m in Consumer Transactions in 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 1:02 PM on Saturday, May 23rd, 2020
  • Unified has a database of over one million customers and facilitated over $375,000,000(Cdn) in consumer transactions
  • Unified’s platform generates revenue from licensing, marketing and product fulfillment fees, supporting brands in skin care, essential oils, men’s health, weight management and CBD

VANCOUVER, BC / ACCESSWIRE / May 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company”) is excited to announce it has entered into a Letter of Intent (the “LOI”) dated May 21, 2020, to evaluate the acquisition (the “Proposed Transaction”) of Unified Funding, LLC (“Unified”). Since inception in 2015, Unified has generated a database of over one million customers and has facilitated over Cdn$375,000,000 in consumer transactions. Powered by its proprietary technology platform, Unified has created an eCommerce ecosystem to scale its brands and achieve profitability targets through data analysis, strategic customer acquisition and supply chain management. Founded by partners with more than a decade of eCommerce and technology experience, Unified has rapidly grown into a formidable business focused on aggressive expansion in the natural health products market. Unified’s diverse platform generates revenue from; licensing, marketing and product fulfillment fees supporting brands in skin care, essential oils, men’s health, weight management and CBD including MOTA’s recently audited Nature’s Exclusive brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada closing exchange rate on May 22, 2020 of US$1.00:Cdn$1.3892.

“A transaction with Unified is another step forward in our expansion as a global eCommerce business. This is the platform and personnel necessary for MOTA to launch and grow brands, such as Nature’s Exclusive, which we acquired from Unified in January of 2020. Unified has developed a comprehensive eCommerce platform that is ideally suited for the natural health products sector. Integration of their platform and the personnel to run it will allow us to rapidly deploy new products and expand into new natural health product segments and markets,” stated Ryan Hoggan, CEO of the Company.

Beyond Unified’s comprehensive eCommerce technology platform, their services assist brands with launching and scaling customer acquisition strategies. Through a worldwide network of media partners, Unified is able to closely monitor market trends to guide product innovation and marketing strategies that yield profitable results.

“We have created a very comprehensive eCommerce platform with a team of data analysis, strategic customer acquisition and supply chain management experts that has been proven effective for rapid expansion of natural health brands. We are hopeful that a transaction with Mota will allow our group to use our skills to expand into additional international markets, create new natural health brands and reach more consumers. Mota’s access to capital markets to raise growth capital to invest in customer acquisition will give us a distinct advantage to quickly scale, diversify and expand into new high growth product offerings,” stated Kevin Keranen, Chairman of Unified.

Readers are cautioned that the LOI entered into with Unified does not set forth the terms of the Proposed Transaction, nor have such terms been finalized. Completion of the Proposed Transaction is subject to a number of conditions, including, not limited to, completion of due diligence, negotiation of definitive documentation, and the receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied and there can be no assurance that the Proposed Transaction will be completed at all.

The Proposed Transaction is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding its review of Unified, and the Proposed Transaction, as that information becomes available.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

About Unified Funding, LLC

Founded in 2015 by partners with more than a decade of eCommerce and technology experience, Unified has rapidly grown into a formidable organization focused on aggressive expansion in the natural health products market. Powered by its proprietary technology platform, the company has created an eCommerce ecosystem to scale its brands and achieve profitability targets through data analysis, strategic customer acquisition and supply chain management. For more information about Unified, please visit https://www.unifiedbrandlab.com/.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected]or www.motaventuresco.com

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Signs LOI to Acquire Ecommerce Platform Leader Unified Funding, LLC, Which Generated $96.5m in Consumer Transactions in 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

« Older Entries
Newer Entries »